444 related articles for article (PubMed ID: 29538002)
1. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
[TBL] [Abstract][Full Text] [Related]
2. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
[TBL] [Abstract][Full Text] [Related]
3. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
Bolek T; Samoš M; Škorňová I; Stančiaková L; Staško J; Korpallová B; Galajda P; Kubisz P; Mokáň M
J Thromb Thrombolysis; 2019 Jan; 47(1):140-145. PubMed ID: 30288664
[TBL] [Abstract][Full Text] [Related]
4. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Škorňová I; Samoš M; Bolek T; Kamenišťáková A; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e122-e127. PubMed ID: 34173805
[TBL] [Abstract][Full Text] [Related]
5. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
[TBL] [Abstract][Full Text] [Related]
6. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
7. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
12. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?
Samoš M; Bolek T; Stančiaková L; Škorňová I; Ivanková J; Kovář F; Galajda P; Kubisz P; Staško J; Mokáň M
Diabetes Res Clin Pract; 2018 Jan; 135():172-177. PubMed ID: 29175298
[TBL] [Abstract][Full Text] [Related]
13. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
14. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Steppich B; Dobler F; Brendel LC; Hessling G; Braun SL; Steinsiek AL; Deisenhofer I; Hyseni A; Roest M; Ott I
J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
[TBL] [Abstract][Full Text] [Related]
15. Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation.
Schapkaitz E; Ter Morshuizen B; Mc Cree M; F Jacobson B
Clin Appl Thromb Hemost; 2024; 30():10760296241249167. PubMed ID: 38659339
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
17. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
[TBL] [Abstract][Full Text] [Related]
18. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]